Puma Biotechnology sinks after Europe unlikely to OK breast cancer drug - Chemdiv
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | BioSpace
Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | FiercePharma
Neratinib Plus Capecitabine Approved for HER2-Positive Metastatic Breast Cancer
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology expands cohorts in phase II SUMMIT trial of Neratinib - Pharmaceutical Business review
Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
Puma Biotechnology
Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer
Puma Biotechnology
Puma Biotechnology expands cohorts in phase II SUMMIT trial of Neratinib – Pharma News HQ
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Nasdaq
Puma Biotechnology
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology: Investors Didn't Like The EU/Africa Partnership Terms, But The Risk/Reward Is Attractive (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Surging
Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI | Business Wire
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotechnology Files NDS For NERLYNX In Canada
Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® ( neratinib) | Business Wire
Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI | Business Wire
